House Moves Closer To Senate On FDA Bill
This article was originally published in The Gray Sheet
Executive Summary
The chart compares provisions in the latest available versions of House and Senate FDA user fee reauthorization and reform bills.
You may also be interested in...
Fireworks Kept At Bay As Congress Pushes To Enact FDA Reforms By July 4
Bipartisan FDA user fee reauthorization and reform legislation sailed unanimously through the House Energy and Commerce Committee May 10, with many similarities to a Senate version that has also passed out of committee.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.